Live price temporarily unavailable.
Avenue Therapeutics (ATXI) is a Health Care company. Latest news and coverage below.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | — | — | — | — | — | — | $0 | $1.40M |
| Operating income | −$2.38M | −$11.4M | −$21.8M | −$26.3M | −$5.21M | −$3.74M | −$8.04M | −$14.5M | −$11.3M | −$3.08M |
| Operating margin | — | — | — | — | — | — | — | — | — | −219.6% |
| Net income | −$3.18M | −$12.3M | −$21.5M | −$25.9M | −$5.15M | −$3.73M | −$3.55M | −$10.4M | −$11.7M | −$2.91M |
| Net margin | — | — | — | — | — | — | — | — | — | −207.2% |
| EPS (diluted) | −$249.75 | −$416.25 | −$472.50 | −$371.25 | −$4.65 | −$3.30 | — | — | — | — |
| Balance sheet | ||||||||||
| Cash and equivalents | $197.0K | $11.8M | $2.67M | $8.74M | $3.13M | $3.76M | $6.71M | $1.78M | $2.59M | $2.85M |
| Total assets | $197.0K | $22.2M | $4.53M | $8.91M | $3.25M | $3.96M | $6.84M | $1.85M | $2.67M | $2.93M |
| Total liabilities | $8.45M | $2.79M | $5.16M | $2.12M | $886.0K | $509.0K | $3.58M | $1.20M | $816.0K | $1.10M |
| Shareholders' equity | −$8.25M | $19.4M | −$631.0K | $6.80M | $2.36M | $3.45M | $3.90M | $1.58M | — | $1.83M |
| Cash flow | ||||||||||
| Operating cash flow | −$1.63M | −$6.80M | −$18.2M | −$26.3M | −$4.61M | −$3.75M | −$7.60M | −$9.45M | −$9.03M | −$1.83M |
| Share buybacks | — | — | — | — | — | — | $1.10M | $0 | — | — |
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25†Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26†Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | $0 | $1.40M | $0 | — | $0 | $0 |
| Growth (year over year) | — | — | — | — | — | — | — | −100.0% |
| Operating income | −$3.16M | — | −$1.91M | $297.0K | −$724.0K | — | −$714.0K | −$707.0K |
| Operating margin | — | — | — | 21.2% | — | — | — | — |
| Net income | −$3.08M | — | −$1.85M | $335.0K | −$683.0K | — | −$695.0K | −$690.0K |
| Net margin | — | — | — | 23.9% | — | — | — | — |
| Balance sheet | ||||||||
| Cash and equivalents | $2.60M | $2.59M | $3.50M | $3.33M | $3.71M | $2.85M | $2.42M | $1.94M |
| Total assets | $2.63M | $2.67M | $3.59M | $4.16M | $3.73M | $2.93M | $2.47M | $1.98M |
| Total liabilities | $973.0K | $816.0K | $1.26M | $1.33M | $1.42M | $1.10M | $1.27M | $1.41M |
| Shareholders' equity | $2.61M | — | $3.51M | $4.06M | $3.56M | $1.83M | $1.20M | $569.0K |
| Cash flow | ||||||||
| Operating cash flow | −$2.89M | — | −$1.19M | −$176.0K | $383.0K | — | −$438.0K | −$475.0K |
From Avenue Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Avenue Therapeutics in our feed yet.